Author Archives: Kerri Fitzgerald

Accuracy of Sestamibi Scans to Determine Parathyroid Pathology Examined

Patients who undergo kidney transplantation may develop tertiary hyperparathyroidism (ThPT) after successful renal transplantation. The incidence of ThPT, typically described as persistent hyperparathyroidism, may be as high as 50% in renal transplantation patients. The hyperparathyroidism often resolves in a few months following transplant, with or without medical treatment. The occurrence of ThPT increases with the duration of dialysis before transplantation ... Read More »

Gene Expression Profiles in Kidney Cell Types Associated with Fabry Disease

Findings from a recent study suggest that globotriaosylceramide (Gb3) and deacylated Gb3 (lyco-Gb3) lead to renal fibrosis in Fabry disease through different biochemical modulations. YJ Shin, MD, and colleagues reported study results online in Molecular Medicine Reports [doi:10.3892/mmr.2015.4010. Epub ahead of print]. Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the gene encoding the a-galactosidase A ... Read More »

Outcomes with SLED and CRRT Comparable in Patients with AKI

In a recent small, nonrandomized study, researchers found that clinical outcomes for patients treated with sustained low-efficiency dialysis (SLED) were similar to those for patients treated with continuous renal replacement therapy (CRRT). Abhijat Kitchlu, MD, and colleagues reported study results online in BMC Nephrology [doi:10.1186/s12882-015-0123-4]. CRRT, which permits gradual fluid and solute removal, has been shown to have greater hemodynamic ... Read More »

Midlife Blood Pressure Associated with Late-Life GFR

Factors other than age may account for the high prevalence of chronic kidney disease (CKD) in the elderly. That was among the findings of a cross-sectional analysis of a substudy of a prospective cohort. Results of the analysis were reported by Lesley A. Inker, MD, MS, and colleagues in the American Journal of Kidney Diseases [2015;66(2):240-248]. Among the elderly population, ... Read More »

Measurement of Novel Filtration Markers Strong Surrogate for ESRD Risk

There is a strong association between a >30% decline in kidney function assessed using novel filtration markers and the risk of end-stage renal disease (ESRD). That was among the findings of a cohort study conducted recently by Casey M. Rebholz, PhD, MS, MPH, and colleagues. The researchers reported study findings in the American Journal of Kidney Diseases [2015;66(1):47-54]. In clinical ... Read More »

September 2015: Abstract Roundup

DIABETES Finerenone Improves Urinary-Creatinine Ratio                                              JAMA. 2015;314(9):884-894. For patients with diabetic nephropathy who receive an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB), the addition of the medication finerenone resulted in improvement in albuminuria compared with placebo in a recent study. George L. Bakris, MD, and colleagues designed the study to evaluate the safety and efficacy of varying ... Read More »

Phase 3 CRUISE Trials Find Triferic™ Maintains Hemoglobin without Increasing Ferritin

The phase 3 CRUISE trials, published in Nephrology Dialysis Transplantation, determined that Triferic™ administered via dialysate maintains hemoglobin concentration without increasing ferritin. The randomized, single-blind, placebo-controlled studies examined the safety and efficacy of Triferic™ compared with placebo in patients with chronic hemodialysis. In patients receiving Triferic™, the drug was added to the bicarbonate hemodialysis concentrate, while the placebo cohort receiving ... Read More »

PRIME Study Examines the Safety and Efficacy of Triferic™ in Patients with Chronic Hemodialysis

A recent PRIME study published in Kidney International found that Triferic™ (ferric pyrophosphate citrate) administered via dialysate reduced erythropoiesis-stimulating agent (ESA) requirement compared to placebo while maintaining hemoglobin. This 9-month, prospective, randomized, placebo-controlled, double-blind, multicenter trial sought to determine the safety and efficacy of Triferic™ in a total of 103 patients who were randomized to receive Triferic™ (n=52) or placebo ... Read More »